GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (NYSE:RMD) » Definitions » Cyclically Adjusted Price-to-FCF

ResMed (ResMed) Cyclically Adjusted Price-to-FCF : 57.54 (As of Apr. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ResMed Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), ResMed's current share price is $218.06. ResMed's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $3.79. ResMed's Cyclically Adjusted Price-to-FCF for today is 57.54.

The historical rank and industry rank for ResMed's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

RMD' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 34.18   Med: 50.63   Max: 91.58
Current: 48.38

During the past years, ResMed's highest Cyclically Adjusted Price-to-FCF was 91.58. The lowest was 34.18. And the median was 50.63.

RMD's Cyclically Adjusted Price-to-FCF is ranked worse than
56.77% of 229 companies
in the Medical Devices & Instruments industry
Industry Median: 42.75 vs RMD: 48.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

ResMed's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $1.683. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $3.79 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


ResMed Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ResMed's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Cyclically Adjusted Price-to-FCF Chart

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.69 68.47 76.41 62.13 61.38

ResMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.49 62.90 61.38 40.05 45.37

Competitive Comparison of ResMed's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted Price-to-FCF falls into.



ResMed Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ResMed's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=218.06/3.79
=57.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ResMed's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.683/129.4194*129.4194
=1.683

Current CPI (Dec. 2023) = 129.4194.

ResMed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.565 99.695 0.733
201406 0.659 100.560 0.848
201409 0.445 100.428 0.573
201412 0.595 99.070 0.777
201503 0.547 99.621 0.711
201506 0.596 100.684 0.766
201509 0.743 100.392 0.958
201512 0.980 99.792 1.271
201603 0.776 100.470 1.000
201606 0.890 101.688 1.133
201609 0.487 101.861 0.619
201612 0.725 101.863 0.921
201703 0.355 102.862 0.447
201706 0.839 103.349 1.051
201709 0.528 104.136 0.656
201712 0.794 104.011 0.988
201803 0.931 105.290 1.144
201806 0.760 106.317 0.925
201809 0.226 106.507 0.275
201812 0.755 105.998 0.922
201903 0.850 107.251 1.026
201906 0.811 108.070 0.971
201909 0.948 108.329 1.133
201912 0.289 108.420 0.345
202003 1.425 108.902 1.693
202006 2.115 108.767 2.517
202009 0.857 109.815 1.010
202012 0.900 109.897 1.060
202103 1.149 111.754 1.331
202106 1.334 114.631 1.506
202109 -0.664 115.734 -0.743
202112 1.225 117.630 1.348
202203 0.444 121.301 0.474
202206 0.320 125.017 0.331
202209 0.084 125.227 0.087
202212 0.658 125.222 0.680
202303 1.705 127.348 1.733
202306 1.346 128.729 1.353
202309 1.664 129.860 1.658
202312 1.683 129.419 1.683

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ResMed  (NYSE:RMD) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ResMed Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ResMed's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (ResMed) Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Executives
Brett Sandercock officer: Chief Financial Officer 17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154
Michael J. Farrell officer: Chief Executive Officer C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123
Michael J Rider officer: Global General Counsel 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Robert Andrew Douglas officer: President and COO 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Kaushik Ghoshal officer: President, SaaS Business 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
David Pendarvis officer: Chief Administration Officer REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Karen Drexler director C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Justin Leong officer: President, Asia and LATAM C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Desney Tan director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
John Hernandez director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Lucile Blaise officer: President, Sleep & RC Business RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
James Hollingshead officer: President, Sleep Business C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Carol Burt director C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634
Resmed Inc director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123

ResMed (ResMed) Headlines